The purpose of the present study was to determine, by utilizing an animal model of Sjögren's syndrome, whether androgen therapy might ameliorate autoimmune sequelae in the lacrimal gland. Age-matched female MRL/Mp-lpr/lpr mice were administered subcutaneous implants of placebo- or testosterone-containing pellets after the onset of disease. Lacrimal glands and, for comparison, submandibular glands were collected from sacrificed mice immediately prior to androgen administration and following 17 and 34 days of maintained hormone exposure. Tissues were processed for light microscopy and examined with a computer-assisted image analysis system. Results demonstrated that testosterone exposure dramatically reduced lymphocyte infiltration in lacrimal tissue: following 34 days of treatment, the percentage infiltrate had undergone a 12-fold decrease. This hormone action, which was time dependent, involved significant abrogations in both infiltrate size and number. Testosterone administration also induced a significant 2- to 3-fold rise in lacrimal gland weight and acinar area and a 2-fold reduction in acinar density/field, compared to values in placebo-treated controls. In addition, androgen administration significantly decreased the magnitude of lymphocyte infiltration in submandibular glands. Overall, our findings demonstrate that androgen therapy may reverse autoimmune sequelae in lacrimal, as well as submandibular, glands in a mouse model of Sjögren's syndrome.